drugset

drugset / Trial / NCT06533358

A Clinical Study of MT1002 in Subjects With Acute Coronary Syndrome Undergoing PCI

NCT06533358 ↗

Phase 2 Recruiting 20 enrolled Shaanxi Micot Pharmaceutical Technology Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

An Open-label, Sequential Dose Escalation/De-escalation Clinical Trial of MT1002 in Subjects With Acute Coronary Syndrome Undergoing PCI.

Timeline

Start: 2024-02-27
Primary completion: 2024-12
Completion: 2025-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MT1002	Peptide	1.2 mg/kg	Intravenous

Indications